MODERN MEDICINE AND PRACTICE
https://inovatus.es/index.php/ejmmp

EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE
Vol. 4 No. 10 (Oct - 2024) EJMMP ISSN: 2795-921X

INFLUENCE OF PROTON PUMP INHIBITORS IN PATIENTS WITH LIVER CIRRHOSIS

Khaydarova Zarrina Erkinovna
Assistant at the Department of Propaedeutics of Internal Diseases SamSMU. Uzbekistan

Bekmuradova Makhsuda Salkhidinovna
PhD, Assistant at the Department of Propaedeutics of Internal Diseases SamSMU. Uzbekistan

Vafoyeva Nigora Abrorovna
Assistant at the Department of Propaedeutics of Internal Diseases SamSMU. Uzbekistan

Tairov Doston Rustamovich
PhD, Assistant at the Department of Propaedeutics of Internal Diseases, Samarkand State Medical University. Uzbekistan

Astract: Proton pump inhibitors (PPIs) are widely used to manage gastroesophageal reflux disease (GERD) in patients with liver cirrhosis, yet their long-term impact on this vulnerable population remains unclear. The study aimed to assess the association between PPI use and adverse outcomes, including hepatic encephalopathy (HE), Clostridium difficile infection, and vitamin B12 deficiency in cirrhotic patients. Despite evidence linking PPI use to these complications, there remains a knowledge gap regarding the mechanisms involved and optimal management strategies.

In this retrospective cohort study, clinical data from 300 cirrhotic patients on PPI therapy and 100 controls were analyzed. The incidence of HE, infections, and nutrient deficiencies were compared between groups. Findings revealed a significantly higher rate of HE (45% vs. 25%), increased Clostridium difficile infections (12% vs. 5%), and lower B12 levels among PPI users compared to controls ($p < 0.05$).

The results indicate that prolonged PPI therapy may exacerbate cirrhosis-related complications through mechanisms involving gut microbiota disruption and nutrient malabsorption. These findings underscore the need for cautious use of PPIs in cirrhotic patients and suggest the importance of monitoring for adverse effects. Further research is necessary to understand the dose-response relationship and to develop guidelines that balance the benefits of acid suppression with potential risks in this population.

Key words: proton pump inhibitors, liver cirrhosis, hepatic encephalopathy, Clostridium difficile infection, vitamin B12 deficiency, gut-liver axis.

Introduction

Liver cirrhosis is a chronic and progressive condition characterized by the replacement of healthy liver tissue with fibrous scar tissue, leading to a significant decline in liver function. This condition can arise from various etiologies, including chronic viral hepatitis, alcohol abuse, and non-alcoholic fatty liver disease

(NAFLD). The global burden of liver cirrhosis is substantial, with millions of individuals affected worldwide, leading to significant morbidity and mortality. As cirrhosis progresses, patients often experience numerous complications, particularly those related to the gastrointestinal tract. One common complication in this population is gastroesophageal reflux disease (GERD), which occurs due to increased intra-abdominal pressure, altered esophageal motility, and esophageal hypersensitivity. These factors contribute to the regurgitation of gastric contents into the esophagus, resulting in symptoms such as heartburn, chest pain, and dysphagia, which can severely impair the quality of life of patients suffering from liver cirrhosis.

Proton pump inhibitors (PPIs) are a class of medications widely prescribed to reduce gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in the gastric parietal cells. By decreasing gastric acidity, PPIs are effective in managing conditions such as GERD, peptic ulcers, and Zollinger-Ellison syndrome. The mechanism of action involves the binding of PPIs to the proton pump in the stomach lining, thereby preventing the secretion of hydrochloric acid. PPIs have become one of the most commonly prescribed classes of medications worldwide due to their effectiveness and safety profile in the general population. However, the use of PPIs in patients with liver cirrhosis raises specific concerns due to the liver's crucial role in drug metabolism. Given that the liver is responsible for the biotransformation of various drugs, including those in the PPI class, it is essential to assess the safety and efficacy of PPIs in this vulnerable patient population. Alterations in liver function can affect the pharmacokinetics of these medications, potentially leading to increased drug exposure and heightened risk of adverse effects.

Previous studies have explored the benefits of PPI therapy in alleviating GERD symptoms and improving the quality of life for cirrhotic patients. Research has shown that PPI treatment significantly reduces reflux symptoms and the severity of esophagitis in individuals with liver cirrhosis, thus providing relief from discomfort and improving overall patient satisfaction. Furthermore, the therapeutic use of PPIs has been associated with a reduction in complications arising from acid reflux, such as esophageal stricture and Barrett's esophagus, which can further complicate the management of cirrhosis. However, long-term use of PPIs has been associated with several potential adverse effects, including an increased risk of infections (such as Clostridium difficile), renal impairment, and vitamin B12 deficiency. Studies have suggested that chronic acid suppression may disrupt the gut microbiome, leading to dysbiosis and increased susceptibility to infections. Moreover, vitamin B12 deficiency can result in neurological complications and anemia, which are particularly concerning in cirrhotic patients who may already be vulnerable to nutritional deficiencies. Furthermore, the impact of prolonged PPI therapy on the progression of liver disease and the development of hepatic encephalopathy remains inadequately understood, revealing a crucial gap in the existing literature. Hepatic encephalopathy, a neurocognitive disorder stemming from liver dysfunction, poses significant management challenges and may be exacerbated by the use of certain medications, including PPIs.

The primary objective of this study is to thoroughly investigate the implications of PPI therapy in patients with liver cirrhosis, focusing on its effectiveness in managing GERD symptoms while critically assessing the associated risks. This research is novel in its comprehensive evaluation of both the therapeutic benefits and potential complications linked to PPI use in this specific demographic. By synthesizing data from existing studies and new research, this paper aims to clarify the risk-benefit profile of PPIs in liver cirrhosis management. Expected results will not only enhance our understanding of the role of PPIs in liver cirrhosis management but will also provide valuable insights into optimizing treatment strategies for these patients, ultimately aiming to improve their overall quality of life and minimize adverse outcomes.

Methodology

This study followed a retrospective cohort design to assess the impact of proton pump inhibitors (PPIs) on patients with liver cirrhosis. Data was gathered from electronic medical records of patients across three hospitals, supplemented by a meta-analysis of relevant studies.

The study involved 300 patients with liver cirrhosis treated with PPIs for at least six months. A control group of 100 patients with cirrhosis but without PPI use was included for comparison.

- Adults aged 18–80 years.
- Diagnosed with cirrhosis based on **Child-Pugh classification (A, B, C)**.
- On PPI therapy for at least 6 months.

Exclusion Criteria:

- Concurrent H2 receptor antagonist therapy.
- Acute gastrointestinal bleeding in the past 3 months.
- Renal failure or chronic dialysis.

3. Data Collection

Clinical data collected included:

- Assessed liver function using variables:
- Score=Bilirubin+Albumin+INR+Ascites+Encephalopathy\text{Score} = \text{Bilirubin} + \text{Albumin} + \text{INR} + \text{Ascites} + \text{Encephalopathy}Score=Bilirubin+Albumin+INR+Ascites+Encephalopathy
- Dosage and duration of PPI therapy.
- Adverse outcomes: hepatic encephalopathy, Clostridium difficile infections, B12 deficiency.

Data were analyzed using **SPSS version 26.0**. Statistical methods included:

- **Chi-square test** for association between PPI use and adverse outcomes.
- **Student's t-test** for continuous variables like liver enzyme levels.
- **Logistic regression** to adjust for confounders, yielding odds ratios (OR) with 95% confidence intervals (CI): OR=p1−pOR = \frac{p}{1-p}OR=1−pp

where ppp is the probability of developing hepatic encephalopathy.

- **Kaplan-Meier survival analysis** to compare the time-to-event data for developing hepatic encephalopathy, using **a log-rank test** to compare survival curves.

Ethical approval was obtained, and patient data was anonymized. Informed consent was waived due to the retrospective nature of the study.

This simplified methodology ensures efficient and accurate evaluation of PPI effects on cirrhotic patients, combining clinical data and advanced statistical techniques for robust results.

Results

The study evaluated 300 patients with liver cirrhosis who were on proton pump inhibitors (PPIs) and 100 patients in the control group. The average duration of PPI use was 12 months. **Child-Pugh classification** showed that most patients were in classes B and C, indicating moderate to severe liver dysfunction.

The results indicated a significant increase in the incidence of hepatic encephalopathy in patients using PPIs. Among PPI users, 45% developed HE, compared to 25% in the control group (**$p < 0.01$**). This suggests a potential link between prolonged PPI use and the exacerbation of neurological complications in cirrhotic patients.

The analysis also found a higher risk of Clostridium difficile infection among PPI users (12%) compared to the control group (5%) (**p = 0.02**). This is in line with previous research indicating that acid suppression therapy increases the risk of gastrointestinal infections due to changes in gut flora.

Vitamin B12 levels were significantly lower in PPI users, with 38% showing deficiency versus 18% in the control group. This finding supports the hypothesis that long-term PPI use impairs nutrient absorption, particularly in patients with compromised liver function.

The results of this study highlight the dual-edged nature of PPI therapy in patients with liver cirrhosis. While PPIs are effective in managing GERD and preventing esophageal complications, the associated risks, particularly the development of hepatic encephalopathy and increased susceptibility to infections, are concerning.

The significant rise in HE among PPI users can be attributed to the disruption of gut microbiota due to acid suppression, leading to increased intestinal permeability and higher levels of ammonia in the bloodstream. This exacerbates HE, a condition already prevalent in cirrhotic patients due to impaired ammonia metabolism. These findings align with recent studies suggesting that the gut-liver axis plays a critical role in the development of HE in cirrhotic patients on acid suppression therapy.

The higher incidence of infections, particularly Clostridium difficile, raises important clinical considerations. The reduced gastric acidity allows for the overgrowth of pathogenic bacteria, which can be particularly dangerous in immunocompromised cirrhotic patients. The results suggest that PPI use should be carefully evaluated in this population, especially for those with pre-existing gastrointestinal conditions.

Vitamin B12 deficiency in PPI users highlights the long-term effects of acid suppression on nutrient absorption. As cirrhotic patients are already prone to malnutrition, PPI therapy may exacerbate their nutritional deficiencies, further complicating their clinical management. This supports the need for routine monitoring of B12 levels in cirrhotic patients on prolonged PPI therapy.

Further research is needed to explore the underlying mechanisms linking PPI use to hepatic encephalopathy and infections in cirrhotic patients. Longitudinal studies with larger sample sizes are essential to determine causality and to establish clear clinical guidelines for the use of PPIs in this vulnerable population. Future investigations should also focus on alternative acid suppression therapies and their impact on liver function and patient outcomes.

The long-term effects of PPI therapy on liver disease progression and overall survival in cirrhotic patients remain inadequately explored. Additionally, there is a gap in understanding the dose-dependent relationship between PPI use and the development of HE and other complications, which future studies should address.

Conculison

Based on the findings of this study, proton pump inhibitor (PPI) use in patients with liver cirrhosis was associated with a significantly higher incidence of hepatic encephalopathy, increased risk of Clostridium difficile infection, and greater prevalence of vitamin B12 deficiency. These results suggest that while PPIs are effective in managing gastroesophageal reflux disease (GERD) in cirrhotic patients, their prolonged use may exacerbate liver-related complications due to gut microbiota alterations and nutrient malabsorption. Clinicians should carefully weigh the benefits and risks of PPI therapy in cirrhotic patients, ensuring close monitoring for adverse outcomes. Further research is necessary to explore the mechanisms linking PPI use to cirrhosis-related complications, identify safer alternatives, and develop clear clinical guidelines to optimize treatment in this patient population.

List of literatures:

1. Baumgartner, K.; Cooper, J.; Smith, A.; St Louis, J. Liver Disease: Cirrhosis. *FP Essent.* **2021**, *511*, 36–43. [**Google Scholar**] [**PubMed**]
2. Bekmuradova M. S., Bozorova S. A. USE OF PROTON PUMP INHIBITORS IN PATIENTS WITH LIVER CIRRHOSIS AND THEIR IMPACT ON THE MENTAL STATUS OF PATIENTS //World Bulletin of Public Health. – 2023. – T. 29. – C. 75-79.
3. Bekmurodova M. S., Maxmudova X. D. PROTON POMPASI INGIBITORLARINING JIGAR SIRROZI BILAN OG'RIGAN BEMORLARNING RUHIY HOLATIGA TA'SIRI //BIOLOGIYA VA KIMYO FANLARI ILMIY JURNALI. – 2023. – T. 1. – №. 1. – C. 24-30.
4. Cacciola, I. Effects of Proton Pump Inhibitors in Cirrhotic Patients: What Do We Really Know? *Gastroenterology* **2022**, *163*, 47–49. [**Google Scholar**] [**CrossRef**]
5. Chia, C.T.W.; Lim, W.P.; Vu, C.K.F. Inappropriate use of proton pump inhibitors in a local setting. *Singap. Med. J.* **2014**, *55*, 363–366. [**Google Scholar**] [**CrossRef**]
6. Chinzon, D.; Domingues, G.; Tosetto, N.; Perrotti, M. Safety of Long-Term Proton Pump Inhibitors: Facts and Myths. *Arq. Gastroenterol.* **2022**, *59*, 219–225. [**Google Scholar**] [**CrossRef**] [**PubMed**]
7. Cole, H.L.; Pennycook, S.; Hayes, P.C. The impact of proton pump inhibitor therapy on patients with liver disease. *Aliment. Pharmacol. Ther.* **2016**, *44*, 1213–1223. [**Google Scholar**] [**CrossRef**] [**PubMed**]
8. De Roza, M.A.; Kai, L.; Kam, J.W.; Chan, Y.H.; Kwek, A.; Ang, T.L.; Hsiang, J.C. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. *World J. Gastroenterol.* **2019**, *25*, 4933–4944. [**Google Scholar**] [**CrossRef**]
9. Dultz, G.; Piiper, A.; Zeuzem, S.; Kronenberger, B.; Waidmann, O. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. *Aliment. Pharmacol. Ther.* **2015**, *41*, 459–466. [**Google Scholar**] [**CrossRef**]
10. Dutta, A.K.; Sharma, V.; Jain, A.; Elhence, A.; Panigrahi, M.K.; Mohta, S.; Kirubakaran, R.; Philip, M.; Goenka, M.; Bhatia, S.; et al. Inappropriate use of proton pump inhibitors in clinical practice globally: A systematic review and meta-analysis. *Gut* **2024**. [**Google Scholar**] [**CrossRef**]
11. Freedberg, D.E.; Kim, L.S.; Yang, Y.-X. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. *Gastroenterology* **2017**, *152*, 706–715. [**Google Scholar**] [**CrossRef**]
12. Gamelas, V.; Salvado, V.; Dias, L. Prescription Pattern of Proton Pump Inhibitors at Hospital Admission and Discharge. *GE Port. J. Gastroenterol.* **2019**, *26*, 114–120. [**Google Scholar**] [**CrossRef**]
13. García Rodríguez, L.A.; Lanas, A.; Soriano-Gabarró, M.; Vora, P.; Cea Soriano, L. Effect of Proton Pump Inhibitors on Risks of Upper and Lower Gastrointestinal Bleeding among Users of Low-Dose Aspirin: A Population-Based Observational Study. *J. Clin. Med.* **2020**, *9*, 928. [**Google Scholar**] [**CrossRef**]
14. Garcia-Saenz-de-Sicilia, M.; Sanchez-Avila, F.; Chavez-Tapia, N.-C.; Lopez-Arce, G.; Garcia-Osogobio, S.; Ruiz-Cordero, R.; Tellez-Avila, F.-I. PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis. *World J. Gastroenterol.* **2010**, *16*, 5869–5873. [**Google Scholar**] [**CrossRef**] [**PubMed**]

15. Ginès, P.; Krag, A.; Abraldes, J.G.; Solà, E.; Fabrellas, N.; Kamath, P.S. Liver cirrhosis. *Lancet* **2021**, *398*, 1359–1376. [**Google Scholar**] [**CrossRef**] [**PubMed**]
16. Goel, G.A.; Deshpande, A.; Lopez, R.; Hall, G.S.; van Duin, D.; Carey, W.D. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. *Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* **2012**, *10*, 422–427. [**Google Scholar**] [**CrossRef**]
17. Hsiang, J.C.; Gane, E.J.; Bai, W.W.; Gerred, S.J. Type 2 diabetes: A risk factor for liver mortality and complications in hepatitis B cirrhosis patients. *J. Gastroenterol. Hepatol.* **2015**, *30*, 591–599. [**Google Scholar**] [**CrossRef**]
18. Hwang, S.J.; Lee, D.H.; Koh, S.J.; Kim, J.W.; Park, H.S.; Kim, B.G.; Lee, K.L. Correlation Between Proton Pump Inhibitors and the Complications of Liver Cirrhosis: A Systematic Review and Meta-Analysis. *Turk. J. Gastroenterol.* **2022**, *33*, 44–52. [**Google Scholar**] [**CrossRef**]
19. Khabibovna Y. S., Salkhidinovna B. M. Effects of proton pump inhibitors on hepatic encephalopathy in patients with cirrhosis //World Bulletin of Public Health. – 2022. – T. 9. – C. 230-233.
20. Khudoyberdievich, Ziyadullaev Shukhrat, Bekmuradova Makhsuda Salkhidinovna, and Toirov Doston Rustamovich. "Effect of Proton Pump Inhibitors on Hepatic Encephalopathy in Cirrhotic Patients with Concomitant Gastroduodenal Disorders." *American Journal of Medicine and Medical Sciences* 13.2 (2023): 112-118.
21. Lanza, F.L.; Chan, F.K.L.; Quigley, E.M.M.; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. *Am. J. Gastroenterol.* **2009**, *104*, 728–738. [**Google Scholar**]
22. Li, H.; Li, N.; Jia, X.; Zhai, Y.; Xue, X.; Qiao, Y. Appropriateness and Associated Factors of Stress Ulcer Prophylaxis for Surgical Inpatients of Orthopedics Department in a Tertiary Hospital: A Cross-Sectional Study. *Front. Pharmacol.* **2022**, *13*, 881063. [**Google Scholar**] [**CrossRef**]
23. Lodato, F.; Azzaroli, F.; Girolamo, M.D.; Feletti, V.; Cecinato, P.; Lisotti, A.; Festi, D.; Roda, E.; Mazzella, G. Proton pump inhibitors in cirrhosis: Tradition or evidence based practice? *World J. Gastroenterol.* **2008**, *14*, 2980–2985. [**Google Scholar**] [**CrossRef**] [**PubMed**]
24. Mahmud, N.; Serper, M.; Taddei, T.H.; Kaplan, D.E. The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study. *Gastroenterology* **2022**, *163*, 257–269. [**Google Scholar**] [**CrossRef**]
25. National Institute for Health and Care Excellence (NICE). *Gastro-Oesophageal Reflux Disease and Dyspepsia in Adults: Investigation and Management*; NICE Clinical Guidelines, No. 184; National Institute for Health and Care Excellence (NICE): London, UK, 2019. [**Google Scholar**]
26. Nazarov, Feruz Yusufovich, and Zarina Erkinovna Xaydarova. "OSHQOZON VA ICHAK YARA KASALLIKLARI BOR BEMORLARDA SUYAKLAR MINERAL ZICHLIGINING BUZILISHI." *Oriental renaissance: Innovative, educational, natural and social sciences* 2.Special Issue 4-2 (2022): 1037-1044.
27. Sakata, Y.; Tsuruoka, N.; Takedomi, H.; Akutagawa, T.; Shimoda, R.; Esaki, M.; Fujimoto, K. A Study on the Status of Proton Pump Inhibitor Prescriptions Using Diagnosis Procedure Combination Data in Japan. *Digestion* **2020**, *101*, 308–315. [**Google Scholar**] [**CrossRef**] [**PubMed**]

28. Salhiddinovna, B. M., Alisherovna, K. M., Tashtemirovna, E. M. M., & Tatlibayevich, Y. S. (2023). Hepatic Encephalopathy and Quality of Life of Patients With Viral Cirrhosis of the Liver. *Miasto Przyszłości*, *35*, 1-5.

29. Salkhidinovna B. M. Assessment of the dynamics of hepatic encephalopathy in patients with cirrhosis before and after treatment in stationary. – 2022.

30. Salkhidinovna B. M. et al. Challenges and Treatment in Liver Diseases //Miasto Przyszłości. – 2024. – Т. 52. – С. 576-582.

31. Salkhidinovna B. M. et al. Psychological Impacts and Treatment Strategies in Patients With Liver Cirrhosis //Research Journal of Trauma and Disability Studies. – 2024. – Т. 3. – №. 9. – С. 140-146.

32. Salkhidinovna B. M., Nizomitdinovich K. S. ASSESSMENT OF THE DYNAMICS OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS BEFORE AND AFTER IN-HOSPITAL TREATMENT.

33. Savarino, V.; Mela, G.S.; Zentilin, P.; Mansi, C.; Mele, M.R.; Vigneri, S.; Cutela, P.; Vassallo, A.; Dallorto, E.; Celle, G. Evaluation of 24-hour gastric acidity in patients with hepatic cirrhosis. *J. Hepatol.* **1996**, *25*, 152–157. [**Google Scholar**] [**CrossRef**] [**PubMed**]

34. Scarpignato, C.; Gatta, L.; Zullo, A.; Blandizzi, C. Effective and safe proton pump inhibitor therapy in acid-related diseases—A position paper addressing benefits and potential harms of acid suppression. *BMC Med.* **2016**, *14*, 179. [**Google Scholar**] [**CrossRef**] [**PubMed**]

35. Thurber, K.M.; O Otto, A.; Stricker, S.L. Proton pump inhibitors: Understanding the associated risks and benefits of long-term use. *Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm.* **2023**, *80*, 487–494. [**Google Scholar**] [**CrossRef**]

36. Toshtemirovna, E. M. M., Alisherovna, K. M., Erkinovna, K. Z., & Xudoyberdiyevich, G. X. (2022). DIAGNOSIS OF CIRRHOTIC CARDIOMYOPATHY. *Spectrum Journal of Innovation, Reforms and Development*, *10*, 141-147.

37. Wang, T.; Huang, S.; Wu, C.; Wang, N.; Zhang, R.; Wang, M.; Mao, D. Intestinal Microbiota and Liver Diseases: Insights into Therapeutic Use of Traditional Chinese Medicine. *Evid. Based Complement. Altern. Med.* **2021**, *2021*, 6682581. [**Google Scholar**] [**CrossRef**]

38. Xudoyberdiyevich, Gafforov Xudoyor, and Vafoyeva Nigora Abrorovna. "Jigar Sirrosi Kasalligida Yurakning Sistolik Va Diastolik Disfunktsiyasining Ahamiyati." *Journal of cardiorespiratory research* 2.1 (2021): 67-69.

39. Yarmatov, Suvon Totliboyevich. "Yurak Ishemik Kasalligi Va Bachadon Miomasi Bo'lgan Bemorlarni Davolashda Antikougulyant Va Antitrombositar Terapiyani O'tkazish Bo'yicha Klinik Kuzatuvni Olib Borish." *Scientific progress* 2.3 (2021): 792-797.

40. Бекмурадова М. С., Гаффаров Х. Х., Ярматов С. Т. Ошқозон-ичак тракти зарарланиши устунлиги билан кечган коронавирус инфекциясидан кейинги ҳолатни даволашнинг ўзига хосликлари //Scientific progress. – 2021. – Т. 2. – №. 1. – С. 489-493.

41. Бекмурадова М. С., Махмудова Х. Д. ВЛИЯНИЕ ИНГИБИТОРОВ ПРОТОННОЙ ПОМПЫ НА МЕНТАЛЬНЫЙ СТАТУС БОЛЬНЫХ ЦИРРОЗОМ ПЕЧЕНИ //World of Scientific news in Science. – 2023. – Т. 1. – №. 2. – С. 128-138.